Pharmaceutical Technology3 天
Dalnicastobart by Lyvgen Biopharma for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Dalnicastobart is under clinical development by Lyvgen Biopharma and currently in Phase I for Oral Cavity (Mouth) Cancer.
Pharmaceutical Technology9 天
Nivolumab by Bristol-Myers Squibb for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Oral Cavity (Mouth) Cancer.